CDC Advisory Panel’s Shift on Hepatitis B Vaccine Sparks Debate
The CDC advisory panel’s decision to adjust the hepatitis B vaccine guidance marks a pivotal shift in public health policy. Previously, a universal recommendation ensured all newborns received the vaccine regardless of the mother’s status. Now, the focus shifts to maternal testing, sparking discussions on its implications for public trust and healthcare practices. This change affects healthcare decisions across Canada, where the policy is currently seeing significant interest.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →